Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)

PHASE4TerminatedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

macitentan

used in open label

DRUG

tadalafil

used in open label

Trial Locations (18)

13005

Hôpital Timone Adultes, Marseille

14033

Hôpital Côte de Nacre, Caen

21079

CHU Site du Bocage, Dijon

25030

Hôpital Jean Minjoz, Besançon

31059

Hôpital Larrey, Toulouse

33604

Hôpital de Haut Levêque, Bordeaux

34929

Hôpital Arnaud de Villeneuve, Montpellier

35033

Hôpital Pontchaillou, Rennes

37044

Hôpital Bretonneau, Tours

38700

Hôpital Albert Michallon, Grenoble

42277

Hôpital Nord, Saint-Priest-en-Jarez

51092

Hôpital Robert Debré, Reims

67091

Hôpital Civil, Strasbourg

69677

Hôpital Louis Pradel, Lyon

76031

Hôpital Charles Nicolle, Rouen

86021

CHR La Miletrie, Poitiers

87042

Hôpital Dupuytren, Limoges

94270

Hôpital Bicètre, Le Kremlin-Bicêtre

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY